Physical capacity increase in patients with heart failure is associated with improvement in muscle sympathetic nerve activity
Carregando...
Citações na Scopus
5
Tipo de produção
article
Data de publicação
2023
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER IRELAND LTD
Autores
SALES, Allan R. K.
ANTUNES-CORREA, Ligia M.
UENO-PARDI, Linda M.
TREVIZAN, Patricia F.
FRANCO, Fabio G. Mello
Citação
INTERNATIONAL JOURNAL OF CARDIOLOGY, v.378, p.48-54, 2023
Resumo
Background: Exercise training improves physical capacity in patients with heart failure with reduced ejection fraction (HFrEF), but the mechanisms involved in this response is not fully understood. The aim of this study was to determine if physical capacity increase in patients HFrEF is associated with muscle sympathetic nerve activity (MSNA) reduction and muscle blood flow (MBF) increase. Methods: The study included 124 patients from a 17-year database, divided according to exercise training status: 1) exercise-trained (ET, n = 83) and 2) untrained (UNT, n = 41). MSNA and MBF were obtained using microneurography and venous occlusion plethysmography, respectively. Physical capacity was evaluated by cardiopulmonary exercise test. Moderate aerobic exercise was performed 3 times/wk. for 4 months. Results: Exercise training increased peak oxygen consumption (VO2, 16.1 +/- 0.4 vs 18.9 +/- 0.5 mL.kg(-1).min(-1), P < 0.001), LVEF (28 +/- 1 vs 30 +/- 1%, P = 0.027), MBF (1.57 +/- 0.06 vs 2.05 +/- 0.09 mL.min(-1).100 ml(-1), P < 0.001) and muscle vascular conductance (MVC, 1.82 +/- 0.07 vs 2.45 +/- 0.11 units, P < 0.001). Exercise training significantly decreased MSNA (45 +/- 1 vs 32 +/- 1 bursts/min, P < 0.001). The logistic regression analyses showed that MSNA [(OR) 0.921, 95% CI 0.883-0.962, P < 0.001] was independently associated with peak VO2. Conclusions: The increase in physical capacity provoked by aerobic exercise in patients with HFrEF is associated with the improvement in MSNA.
Palavras-chave
Heart failure, Exercise training, Peak oxygen consumption, Muscle sympathetic nerve activity
Referências
- Antunes-Correa LM, 2020, J CACHEXIA SARCOPENI, V11, P89, DOI 10.1002/jcsm.12495
- Antunes-Correa LM, 2017, EUR J PREV CARDIOL, V24, P365, DOI 10.1177/2047487316683530
- Antunes-Correa LM, 2014, AM J PHYSIOL-HEART C, V307, pH1655, DOI 10.1152/ajpheart.00136.2014
- Antunes-Correa LM, 2012, EUR J PREV CARDIOL, V19, P822, DOI 10.1177/1741826711414626
- Antunes-Correa LM, 2010, EUR J HEART FAIL, V12, P58, DOI 10.1093/eurjhf/hfp168
- Barretto ACP, 2009, INT J CARDIOL, V135, P302, DOI 10.1016/j.ijcard.2008.03.056
- Belardinelli R, 1999, CIRCULATION, V99, P1173, DOI 10.1161/01.CIR.99.9.1173
- Bozkurt B, 2021, J AM COLL CARDIOL, V77, P1454, DOI 10.1016/j.jacc.2021.01.030
- Chua TP, 1997, J AM COLL CARDIOL, V29, P1585, DOI 10.1016/S0735-1097(97)00078-8
- Cunha TF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041701
- Franco FGD, 2006, EUR J HEART FAIL, V8, P851, DOI 10.1016/j.ejheart.2006.02.009
- DELIUS W, 1972, ACTA PHYSIOL SCAND, V84, P82, DOI 10.1111/j.1748-1716.1972.tb05158.x
- DIBNERDUNLAP ME, 1992, CIRCULATION, V86, P1929, DOI 10.1161/01.CIR.86.6.1929
- dos Santos MR, 2016, MAYO CLIN PROC, V91, P575, DOI 10.1016/j.mayocp.2016.02.014
- Gielen S, 2003, J AM COLL CARDIOL, V42, P861, DOI 10.1016/S0735-1097(03)00848-9
- Groehs RV, 2015, AM J PHYSIOL-HEART C, V308, pH1096, DOI 10.1152/ajpheart.00723.2014
- Lavie CJ, 2004, AM J CARDIOL, V93, P588, DOI 10.1016/j.amjcard.2003.11.023
- Liu JL, 2000, CIRCULATION, V102, P1854
- Malhotra R, 2016, JACC-HEART FAIL, V4, P607, DOI 10.1016/j.jchf.2016.03.022
- Marcus NJ, 2015, AM J PHYSIOL-HEART C, V309, pH259, DOI 10.1152/ajpheart.00268.2015
- McDonagh TA, 2021, EUR HEART J, V42, DOI 10.1093/eurheartj/ehab670
- Middlekauff HR, 2010, CIRC-HEART FAIL, V3, P537, DOI 10.1161/CIRCHEARTFAILURE.109.903773
- Middlekauff HR, 1997, CIRCULATION, V96, P1835, DOI 10.1161/01.CIR.96.6.1835
- Murphy SP, 2020, JAMA-J AM MED ASSOC, V324, P488, DOI 10.1001/jama.2020.10262
- Narkiewicz K, 1999, CIRCULATION, V100, P2514, DOI 10.1161/01.CIR.100.25.2514
- Negrao CE, 2015, AM J PHYSIOL-HEART C, V308, pH792, DOI 10.1152/ajpheart.00830.2014
- Organization WH, 2020, GLOBAL HLTH ESTIMATE
- Pan YX, 2007, HYPERTENSION, V49, P519, DOI 10.1161/01.HYP.0000256955.74461.93
- Piepoli MF, 2013, EUR HEART J, V34, P486, DOI 10.1093/eurheartj/ehs463
- Rondon MUPB, 2006, AM J HYPERTENS, V19, P951, DOI 10.1016/j.amjhyper.2006.02.001
- Roveda F, 2003, J AM COLL CARDIOL, V42, P854, DOI 10.1016/S0735-1097(03)00831-3
- Sales ARK, 2020, CIRC-HEART FAIL, V13, DOI 10.1161/CIRCHEARTFAILURE.120.007121
- Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358
- Taylor RS, 2019, J AM COLL CARDIOL, V73, P1430, DOI 10.1016/j.jacc.2018.12.072
- Trevizan PF, 2021, ESC HEART FAIL, V8, P3845, DOI 10.1002/ehf2.13478
- Ueno LM, 2009, SLEEP, V32, P637, DOI 10.1093/sleep/32.5.637
- van Bilsen M, 2017, EUR J HEART FAIL, V19, P1361, DOI 10.1002/ejhf.921
- Wang Y, 2014, HEART FAIL REV, V19, P187, DOI 10.1007/s10741-012-9368-1